Interestingly, C/EBPδ may either act in a tumour‐specific manner as a tumour promotor [4, 5, 6] or tumour suppressor [7, 8, 9, 10, 11, 12, 13, 14, 15] and C/EBPδ activity may thus need to be inhibited or enhanced to achieve (pre)clinical relevance. The gene discussed is CEBPD; the disease is neoplasm.